Prabu Rajagoapalan, Shri Vidya Shyam Prasad, Gokul Raj, Nithish Kumar C, Shyamprasad Kodimule and Raksha Sunhare*

Development and Research Centre-Probiotics, Vidya Herbs Pvt Ltd, No. 102B & 105B, Pharmaceuticals SEZ Industrial Area, KIDB, Hassan, 573201 Karnataka, India

*Corresponding Author: RRaksha Sunhare, Development and Research Centre-Probiotics, Vidya Herbs Pvt Ltd, No. 102B & 105B, Pharmaceuticals SEZ Industrial Area, KIDB, Hassan, 573201 Karnataka, India.

Received: March 03, 2026; Published: March 31, 2026

Abstract

This study aimed to investigate the hepatic protective and therapeutic potential of Bacillus coagulans VHBAX in a zebrafish model of liver cirrhosis. Adult zebrafish were exposed to 0.5% ethanol to induce liver cirrhosis, and the treatment group received probiotic supplementation, with outcomes compared to control and ethanol-induced groups. The effects of supplementation were evaluated through liver histopathology, liver function markers, hepatic lipid accumulation, gut permeability markers, and inflammasome- related parameters. Probiotic administration resulted in marked improvement in liver histology, significant reduction in liver injury biomarkers, decreased lipid accumulation within hepatic tissues, modulation of gut permeability markers indicating restoration of intestinal integrity, and regulation of inflammasome-associated inflammatory responses. Biochemical analyses further confirmed reduced hepatic injury and inflammation, reflecting improved liver function and enhanced lipid metabolism. Overall, the findings suggest that Bacillus coagulans VHBAX exerts a protective effect against ethanol-induced liver damage and may play a beneficial role in mitigating fatty liver disease by reducing inflammation, improving hepatic health, and restoring gut barrier function.

Keywords: Bacillus coagulans; Gut Dysbiosis; Liver Cirrhosis; Liver Function Markers; Probiotics; VHBAX; Zebrafish Model

References

1. Tsochatzis Emmanuel A., et al. “Liver cirrhosis”. The Lancet 383 (2014): 1749-1761.
2. Allweiss Linda., et al. “Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation”. Journal of Hepatology 64 (2016): 1033-1040.
3. Ginès Pere., et al. “Liver cirrhosis”. The Lancet 398 (2021): 1359-1376.
4. Qamar Abbas A. “Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis”. Journal of Clinical Gastroenterology1 (2015): S28-S32.
5. Grüner Nina and Jochen Mattner. “Bile Acids and Microbiota: Multifaceted and Versatile Regulators of the Liver-Gut Axis”. International Journal of Molecular Sciences 22 (2021): 1397.
6. Li Feng., et al. “Microbiome dysbiosis and alcoholic liver disease”. Liver Research 3 (2019): 218-226.
7. Mohamad Nor., et al. “The Effect of Probiotics (MCP® BCMC® Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease”. Nutrients 13 (2021): 3192.
8. Vliegenthart Alexander D., et al. “Zebrafish as model organisms for studying drug-induced liver injury”. British Journal of Clinical Pharmacology 78 (2014): 1217-1227.
9. Folch Jordi., et al. “A simple method for the isolation and purification of total lipides from animal tissues”. Journal of Biological Chemistry 226 (1957): 497-509.
10. Escorcia William., et al. “Quantification of Lipid Abundance and Evaluation of Lipid Distribution in Caenorhabditis elegans by Nile Red and Oil Red O Staining”. Journal of Visualized Experiments 133 (2018): e57352.
11. Chomczynski Piotr and Nicoletta Sacchi. “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction”. Analytical Biochemistry 162 (1987): 156-159.
12. Wei Guo., et al. “Low-dose polystyrene microplastics exposure increases susceptibility to obesity-induced MASLD via disrupting intestinal barrier integrity and gut microbiota homeostasis”. Ecotoxicology and Environmental Safety 299 (2025): 118310.
13. Ren Lili., et al. “Probiotic Lactobacillus rhamnosus GG prevents progesterone metabolite epiallaopregnanolone sulfate-induced hepatic bile acid accumulation and liver injury”. Biochemical and Biophysical Research Communications 520 (2019): 67-72.
14. Sapp Vanessa., et al. “Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition”. Hepatology 60 (2014): 1581-1592.
15. So Jaeyoung., et al. “Attenuating the Epidermal Growth Factor Receptor-Extracellular Signal-Regulated Kinase-Sex-Determining Region Y-Box 9 Axis Promotes Liver Progenitor Cell-Mediated Liver Regeneration in Zebrafish”. Hepatology 73 (2021): 1494-1508.
16. Zou Yuxin., et al. “Exercise Intervention Mitigates Pathological Liver Changes in NAFLD Zebrafish by Activating SIRT1/AMPK/NRF2 Signaling”. International Journal of Molecular Sciences 22 (2021): 10940.

Citation

Citation: Raksha Sunhare.,et al. “A Preclinical Study on Probiotic Intervention in Alcohol-Induced Hepatic Injury". Acta Scientific Microbiology 9.4 (2026): 20-26.

Copyright

Copyright: © 2026 Raksha Sunhare.,et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.